Compare Abbott Laboratories (ABT) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Omnicom Group Inc. — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Omnicom Group Inc. trades at $78.68 (market cap $23.04B). The key difference: Abbott Laboratories is far larger — about 7.2× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| ABT | OMC | |
|---|---|---|
Market Cap | $166.94B | $23.04B |
Sector | Health | Media |
52-Week High | $136.62 | $85.80 |
52-Week Low | $82.57 | $67.27 |
Enterprise Value | $193.69B | $30.27B |
Dividend Yield | 2.63% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
OMC trades at $80.84, up 2.82% today, with a bullish technical outlook supported by moving averages and a consensus price target of $105.75. Recent Q1 2026 earnings beat expectations with EPS of $1.90 versus $1.82 expected, while revenue grew to $17.27B in 2025. The company announced new partnerships with IBM and Netflix, enhancing its media agency footprint, and declared a $0.80 dividend payable in July 2026.
The stock presents value with a low P/E of 12.16 and P/S of 0.93, but net income turned negative in 2025, posing a risk. Analyst sentiment is mixed with 32% buy ratings, reflecting optimism about growth initiatives against profitability concerns. Investors should weigh the attractive valuation and strong cash flow against execution risks in a competitive advertising market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
